No profile data available.
Lantern Pharma Inc. (LTRN) is a healthcare company in the additional cancer treatment drugs industry, based in Dallas, United States, with about 16 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$17.12 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $12.14 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Lantern Pharma reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$12.14 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Actuate Therapeutics, Inc. Common stock (ACTU), AlphaTON Capital Corp. (ATON), Tempest Therapeutics, Inc. (TPST), Intensity Therapeutics, Inc. (INTS).